Y'S THERAPEUTICS
Current Employees Featured
More informations about "Y's Therapeutics"
Organization | Y's Therapeutics, Inc.
Y's Therapeutics, Inc. Report issue. For profit Phase 2. Founded: Tokyo Japan ... Organization Overview. First Clinical Trial. 2006 NCT00298168. First Marketed Drug. None First NDA โฆSee details»
Y's Therapeutics - Crunchbase Company Profile & Funding
Organization. Y's Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. About. Y's Therapeutics. ... Recent News & Activity. There is no recent news or โฆSee details»
Y's Therapeutics - Products, Competitors, Financials, Employees ...
Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and โฆSee details»
Y's Therapeutics Co. Ltd: Contact Details and Business Profile
Y's Therapeutics is a privately held biopharmaceutical company engaged in the R&D of novel therapeutics for the treatment of inflammation-mediated diseases, cancer and other unmet โฆSee details»
YSTH2 - Drug Targets, Indications, Patents - Synapse
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»
Y's Therapeutics (Y's Therapeutics) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่ โฆ
Globally, leading malignant pleural mesothelioma companies such as Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, AstraZeneca, โฆSee details»
Research programme: interleukin-6 inhibitors - Y's Therapeutics
Nov 4, 2017 Y's Therapeutics is conducting a research programme known as YSIL6, to investigate small molecule, oral inhibitors of IL-6 (interleukin-6) for the treatment of ... If your โฆSee details»
Yโs Therapeutics, Inc. Clinical-Stage Compound YSPSL ... - BioSpace
BURLINGAME, Calif., July 20 /PRNewswire/ -- Y's Therapeutics, Inc. said today that the U.S. Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) โฆSee details»
Y's Therapeutics Co. Ltd Management Team | Org Chart
Looking for a particular Y's Therapeutics Co. Ltd employee's phone or email? Find Info Top Y's Therapeutics Co. Ltd Management Employees Yanbao Hu Board Secretary at Y's โฆSee details»
Y's Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse
Explore Y's Therapeutics with its drug pipeline, therapeutic area, technology platform, 1 news. Products. Data. Feature. Plans. Request Demo. Sign Up for Free. Last update 23 Jan 2025. โฆSee details»
Yasuyuki Kusuhara - Director - Y's Therapeutics | LinkedIn
Director at Y's Therapeutics · Experience: Y's Therapeutics · Location: Burlingame · 7 connections on LinkedIn. View Yasuyuki Kusuharaโs profile on LinkedIn, a professional โฆSee details»
Kissei Licenses Monoclonal Antibody from Y's Therapeutics
Y's Therapeutics (www.ysthera.com) and Kissei Pharmaceutical announced on September 10 that they have concluded a license agreement that gives Kissei the exclusive rights to develop โฆSee details»
YS 110 - AdisInsight
Originator Ys Therapeutics Class Antineoplastics; Immunotherapies; Monoclonal antibodies Mechanism of Action Dipeptidyl peptidase 4 inhibitors Orphan Drug Status Orphan designation โฆSee details»
Q1 2025 Y-mAbs Therapeutics Inc Earnings Call - Yahoo Finance
1 day ago Jeff Jones; Analyst; Oppenheimer & Co., Inc. As a reminder, today's conference will be recorded. I would now like to hand the call over to Y-mAbs' Head of IR, Courtney Dugan. โฆSee details»
YSTH2 - AdisInsight - Springer
Sep 23, 2009 27 Jul 2004 Y's Therapeutics has filed an application to begin phase II trials with the Ministry of Health in Germany for Asthma You need to be a logged in or subscribed to view โฆSee details»
Y-mAbs Reports First Quarter 2025 Financial Results and Recent ...
1 day ago Y-mAbs Therapeutics, Inc. - GlobeNewswire - Tue May 13, 5:35AM CDT Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase โฆSee details»
Viralgen Joins Orphan Therapeutics Accelerator Clinical โฆ
8 hours ago The Orphan Therapeutics Accelerator (OTXL) is a patient-centered non-profit biotech focused on obtaining and reinitiating development of promising "shelved" clinical-stage โฆSee details»
Ystop - Drug Targets, Indications, Patents - Synapse - Patsnap
Ystop, Initially developed by Y's Therapeutics, Inc., Now, its global highest R&D status is Discontinued, Therapeutic Areas: Neoplasms. ... Originator Organization. Y's Therapeutics, โฆSee details»
YS-IL6 - Drug Targets, Indications, Patents - Synapse
Last update 19 Apr 2025. YS-IL6. Last update 19 Apr 2025See details»
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue โฆ
1 day ago Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.15 per โฆSee details»